azn201605036k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of May 2016
Commission File Number: 001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
ASTRAZENECA COMPLETES ACQUISITION
OF TAKEDA'S RESPIRATORY BUSINESS
AstraZeneca today announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
|
Media Enquiries
|
|
|
|
Neil Burrows
|
UK/Global
|
+44 20 7604 8032
|
|
Vanessa Rhodes
|
UK/Global
|
+44 20 7604 8037
|
|
Karen Birmingham
|
UK/Global
|
+44 20 7604 8120
|
|
Jacob Lund
|
Sweden
|
+46 8 553 260 20
|
|
Abigail Bozarth
|
US
|
+1 302 885 2677
|
|
Investor Enquiries
|
|
|
|
UK
|
|
|
|
Thomas Kudsk Larsen
|
|
+44 7818 524185
|
|
Eugenia Litz
|
RIA
|
+44 7884 735627
|
|
Nick Stone
|
CVMD
|
+44 7717 618834
|
|
Craig Marks
|
Finance
|
+44 7881 615764
|
|
Christer Gruvris
|
Consensus Forecasts
|
+44 7827 836825
|
|
US
|
|
|
|
Lindsey Trickett
|
Oncology, ING
|
+1 240 543 7970
|
|
Mitch Chan
|
Oncology
|
+1 240 477 3771
|
|
Dial / Toll-Free
|
|
+1 866 381 7277
|
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal
03 May 2016
-ENDS-
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
|
Date: 03 May 2016
|
By: /s/ Adrian Kemp
|
| |
Name: Adrian Kemp
|
| |
Title: Company Secretary
|